Sickle Cell Disease

Hydroxyurea Improves Growth-Factor-Induced Hemoglobin Recovery

Published in Blood Weekly, April 12th, 2001

by Michael Greer, staff medical writer - Adding the DNA synthesis-inhibitor hydroxyurea to growth-factor-based therapy for sickle cell disease can improve hemoglobin recovery, researchers in Illinois have shown.

"Augmentation of the level of fetal hemoglobin (HbF) is considered therapeutic for patients with sickle cell disease," D. Lavelle and colleagues with the U.S. Veterans Administration explained in the journal Experimental Hematology.

Using a primate model, Lavelle et al. found that adding hydroxyurea to treatment with erythropoietin and stem cell factor produced the highest degree of therapeutic Hbf production.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry